Myriad Genetics Research Shows Reduction in Percent of MDD Patients with Hospitalizations after GeneSight Testing
This material has been reviewed for accuracy by: Renee Albers, PhD
In April 2024, Myriad Genetics, Inc. revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test.
“We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “This is the first step in a multi-phase analysis of real-world data to further demonstrate how the GeneSight test may improve clinical outcomes and reduce overall healthcare costs. We expect to share additional study results later this year.”
The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:
- 39% relative reduction in psychiatric-related hospitalizations.
- 29% relative reduction in hospitalizations for any reason.
- Significant reduction in hospitalizations for patients who were switched from a medication with a significant gene-drug interaction to a medication with no or moderate gene-drug interactions.
The study found that, among patients who took the GeneSight test, there was a decrease in the proportion of patients who were prescribed medications with significant gene-drug interactions after taking the test:
- The percentage of patients who were prescribed medications in the significant gene-drug interaction category was reduced from 26.1% to 15.9%
- The percentage of patients who were prescribed medications with no gene-drug interactions increased from 27.5% to 47%.
“These data suggest that healthcare providers are using the GeneSight test to make medication decisions in the real-world,” said Holly Johnson, Ph.D, director of medical affairs at Myriad Genetics. “These results are consistent with multiple, prospective studies demonstrating the utility of pharmacogenomic-guided treatment for improving response and remission rates in major depressive disorder.”
About the Poster
Title: “Impact of Combinatorial Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder”
Authors: Andria L. Del Tredici, PhD; Priya Maheshwari, MS, RPh; Alexander Gutin, PhD; Devika Chawla, PhD; Katie Johansen Taber, PhD; Holly L. Johnson, PhD; Andrew A. Nierenberg, MD
Presenter: Priya Maheshwari, MS, RPh, senior medical information liaison at Myriad Genetics
Conference: American Association of Psychiatric Pharmacists (AAPP) conference in Orlando, FL; presented on Monday, April 8, 2024
About the Study
The study analyzed a data set generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claims from a nationwide data warehouse in the United States. Nearly 21,000 depressed patients met inclusion criteria to be in the study.
The study authors then evaluated this data set with regard to medications prescribed before and after GeneSight testing, as well as hospitalization rates before and after GeneSight testing.
Future analysis of the data will include investigating the impact of post-PGx medication selection on total cost of care for depression.
For more information about this and other topics, please visit:
Our articles are for informational purposes only and are reviewed by our Medical Information team, which includes PharmDs, MDs, and PhDs. Do not make any changes to your current medications or dosing without consulting your healthcare provider.
The GeneSight test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications. As with all genetic tests, the GeneSight test results have limitations and do not constitute medical advice. The test results are designed to be just one part of a larger, complete patient assessment, which would include proper diagnosis and consideration of your medical history, other medications you may be taking, your family history, and other factors.
If you are a healthcare provider and interested in learning more about the GeneSight test, please contact us at 855.891.9415. If you are a patient, please talk with your doctor to see if the GeneSight test may be helpful.
Published: June 8, 2024
Featured Posts
In April 2024, Myriad Genetics, Inc. revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. “We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly... Read More
